Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Masitinib mesylate (AB-1010 mesylate) 是一种生物口服可利用的选择性 c-Kit 抑制剂,IC50 为 200 nM。它还抑制 PDGFRα/β,IC50值为540/800 nM,对 LynB 的 IC50为510 nM。它的毒性低,有抗增殖和促凋亡活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 198 | 现货 | ||
10 mg | ¥ 327 | 现货 | ||
25 mg | ¥ 536 | 现货 | ||
50 mg | ¥ 826 | 现货 | ||
100 mg | ¥ 1,330 | 现货 | ||
200 mg | ¥ 1,990 | 现货 | ||
500 mg | ¥ 3,370 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 317 | 现货 |
产品描述 | Masitinib mesylate (AB-1010 mesylate) is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα/β;LynB,respectively). |
靶点活性 | PDGFRβ:800 nM , PDGFRα:540 nM , c-Kit:200 nM , LynB:510 nM |
体外活性 | In vitro, masitinib had greater activity and selectivity against KIT than imatinib, inhibiting recombinant human wild-type KIT with an half inhibitory concentration (IC50) of 200±40 nM and blocking stem cell factor-induced proliferation and KIT tyrosine phosphorylation with an IC50?of 150±80 nM in Ba/F3 cells expressing human or mouse wild-type KIT. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases. This highly selective nature of masitinib suggests that it will exhibit a better safety profile than other tyrosine kinase inhibitors; indeed, masitinib-induced cardiotoxicity or genotoxicity has not been observed in animal studies. Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib. Furthermore, masitinib potently inhibited human and murine KIT with activating mutations in the juxtamembrane domain.?In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant[1]. |
体内活性 | Masitinib (12.5 mg/kg/d, p.o.) increases overall TTP (time-to-tumor progression) compared with placebo in dogs[2] |
别名 | 甲磺酸马赛替尼, AB-1010 mesylate, 马赛替尼 |
分子量 | 594.75 |
分子式 | C29H34N6O4S2 |
CAS No. | 1048007-93-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (42.03 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6814 mL | 8.4069 mL | 16.8138 mL | 42.0345 mL |
5 mM | 0.3363 mL | 1.6814 mL | 3.3628 mL | 8.4069 mL | |
10 mM | 0.1681 mL | 0.8407 mL | 1.6814 mL | 4.2034 mL | |
20 mM | 0.0841 mL | 0.4203 mL | 0.8407 mL | 2.1017 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Masitinib mesylate 1048007-93-7 Angiogenesis Apoptosis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Src c-Kit PDGFR FAK FGFR SCFR AB 1010 AB 1010 Mesylate 甲磺酸马赛替尼 CD117 AB-1010 mesylate Masitinib Platelet-derived growth factor receptor AB1010 Masitinib Mesylate AB-1010 Inhibitor 马赛替尼 AB1010 Mesylate Fibroblast growth factor receptor inhibit AB-1010 Mesylate inhibitor